Improved outcome with repeated intracoronary injection of bone marrow-derived cells within a registry: rationale for the randomized outcome trial REPEAT.

AIMS Regenerative therapies have evolved as a promising new option in the treatment of post-infarction heart failure. A major limitation of intracoronary application of autologous bone marrow-derived mononuclear cells (BM-MNCs) is that homing of the applied cells is profoundly reduced in patients with post-infarction heart failure compared with patients with acute myocardial infarction. However, early pilot and also randomized controlled trials have demonstrated significant improvements in overall cardiac function. The aim of the present analysis was to quantify a potential mortality risk reduction and reduced hospitalization in order to provide data for a prospective outcome trial. METHODS AND RESULTS The results of an ongoing single-centre registry including 297 post-infarction heart failure patients suggest that repeated intracoronary application of autologous bone marrow-derived cells is associated with a significant better 2-year survival compared with a single BM-MNC application (2-year survival 93.6 vs. 84.0%, P = 0.03). Likewise, mortality is significantly lower at 2-year follow-up compared with the mortality estimated by the use of the Seattle Heart Failure Model (SHFM) in patients receiving repeated BM-MNC application (observed mortality 6.4%, predicted mortality 16.2%, P = 0.02). Although the trend persisted at 3-year follow-up, the mortality reduction was no longer statistically significant between single and repeated treatment (mortality 21.9 vs. 13.7%, P = 0.06). CONCLUSION Repeated intracoronary administration of BM-MNC appears to be associated with improved clinical outcome compared with single treatment at 2 years. This registry provides the rationale for the design of the multicentre randomized, controlled, open-label REPEAT trial, which prospectively compares the effects of single vs. repeated intracoronary application of autologous BM-MNC on total and SHFM-predicted mortality in patients with chronic post-infarction heart failure.

[1]  Mark D. Huffman,et al.  AHA Statistical Update Heart Disease and Stroke Statistics — 2012 Update A Report From the American Heart Association WRITING GROUP MEMBERS , 2010 .

[2]  T. Barington,et al.  Intracoronary Injection of CD34+-Cells in Chronic Ischemic Heart Failure: 7 Years Follow-Up of the DanCell Study , 2014, Cardiology.

[3]  N. Rosenthal,et al.  Preparing the ground for tissue regeneration: from mechanism to therapy , 2014, Nature Medicine.

[4]  V. Jeevanantham,et al.  Adult Bone Marrow Cell Therapy Improves Survival and Induces Long-Term Improvement in Cardiac Parameters: A Systematic Review and Meta-Analysis , 2012, Circulation.

[5]  S. Fisher,et al.  Long-Term Effects of Autologous Bone Marrow Stem Cell Treatment in Acute Myocardial Infarction: Factors That May Influence Outcomes , 2012, PloS one.

[6]  E. Marbán,et al.  Cardiac cell therapy: where we've been, where we are, and where we should be headed. , 2011, British medical bulletin.

[7]  E. Chavakis,et al.  Enhancing the outcome of cell therapy for cardiac repair: progress from bench to bedside and back. , 2010, Circulation.

[8]  D. Mozaffarian,et al.  Maximizing Survival Benefit With Primary Prevention Implantable Cardioverter-Defibrillator Therapy in a Heart Failure Population , 2009, Circulation.

[9]  K. Swedberg,et al.  Survival trends in men and women with heart failure of ischaemic and non-ischaemic origin: data for the period 1987-2003 from the Swedish Hospital Discharge Registry. , 2008, European heart journal.

[10]  T. Barington,et al.  Effect of repeated intracoronary injection of bone marrow cells in patients with ischaemic heart failure ☆ The Danish Stem Cell study—Congestive Heart Failure trial (DanCell‐CHF) , 2008, European journal of heart failure.

[11]  D. Mozaffarian,et al.  Prediction of Mode of Death in Heart Failure: The Seattle Heart Failure Model , 2007, Circulation.

[12]  E. Seifried,et al.  Transcoronary Transplantation of Functionally Competent BMCs Is Associated With a Decrease in Natriuretic Peptide Serum Levels and Improved Survival of Patients With Chronic Postinfarction Heart Failure: Results of the TOPCARE-CHD Registry , 2007, Circulation research.

[13]  A. Zeiher,et al.  Cell isolation procedures matter: a comparison of different isolation protocols of bone marrow mononuclear cells used for cell therapy in patients with acute myocardial infarction. , 2007, European heart journal.

[14]  A. Zeiher,et al.  Transcoronary transplantation of progenitor cells after myocardial infarction. , 2006, The New England journal of medicine.

[15]  D. Mozaffarian,et al.  The Seattle Heart Failure Model: Prediction of Survival in Heart Failure , 2006, Circulation.

[16]  Stefanie Dimmeler,et al.  Unchain my heart: the scientific foundations of cardiac repair. , 2005, The Journal of clinical investigation.

[17]  Douglas L Packer,et al.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. , 2005, The New England journal of medicine.

[18]  M. Pfeffer,et al.  Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme , 2003, The Lancet.

[19]  A. Zeiher,et al.  Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI) , 2002, Clinical research in cardiology : official journal of the German Cardiac Society.

[20]  N. Hollenberg,et al.  Literature alert , 2002 .

[21]  N. Sharpe,et al.  Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. , 2000, Circulation.

[22]  B. Pitt,et al.  The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure , 2000 .

[23]  B. Pitt,et al.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.